By Elina Kingkade, Vice President, Business Development, Inizio Evoke
Pharmageddon brought no shortage of big ideas - AI, patient centricity, omnichannel, innovation. But beneath these familiar themes, a more uncomfortable truth emerged:
The pharmaceutical industry isn’t struggling to innovate. It’s struggling to translate innovation into meaningful impact.
The tension: activity doesn’t equal impact
A consistent undercurrent across discussions was simple but telling:
When investment isn’t real, people can feel it.
Pharma is not lacking activity. There are more tools, more data, and more campaigns than ever before. Yet many organizations are starting to question whether that activity is driving outcomes that truly matter.
The question that continues to surface is:
What is the real patient benefit?
Not the feature. Not the tactic. Not the label of “innovation.”
But the measurable difference in patients’ lives.
Without that clarity, progress risks becoming performative - highly visible, but ultimately disconnected from impact.
From optimization to experience design
One of the most compelling perspectives contrasted two models of progress:
Improving trains makes them faster and more efficient
Designing a Disney experience reimagines the entire journey
Historically, pharma has focused on optimization - refining processes, systems, and outputs. The opportunity ahead lies in something more transformative: rethinking the end-to-end experience for patients and healthcare professionals (HCPs).
This requires a shift in mindset:
Provoking new ideas, not just refining existing ones
Testing and learning at speed
Continuously evolving based on real-world insight
Captured simply: Provoke → Inspire → Capture → Learn → Evolve
AI and the evolving trust equation
AI was a constant theme - but the conversation is evolving.
There is growing recognition that AI can scale expertise and unlock efficiency. But it cannot replace human experience. Without human oversight, it risks becoming self-referential.
As one perspective put it:
“Without humans, AI is just talking to itself.”
There is also increasing awareness of a more nuanced risk: overreliance on AI could erode trust, particularly in patient engagement.
Looking ahead, some envision a future where AI agents influence prescribing decisions, while physicians remain focused on patient care. Whether or not that becomes reality, one thing is clear:
The human role is not diminishing - it is shifting toward judgment, curation, and trust.
Patient centricity: progress with gaps
Patient centricity remains a clear priority - but execution is inconsistent.
Challenges highlighted included:
The need to continuously rejustify investment in patient listening
Systems designed around internal processes rather than patient needs
Communications that prioritize message delivery over meaningful engagement
At the same time, there are strong signals of progress:
Integrating patient insight into day-to-day decision-making
Co-creating content with patients and HCPs
Demonstrating measurable impact when messaging truly resonates
One idea stood out:
Every interaction with a patient is a privilege - yet few systems are designed to reflect that reality.
Collaboration: the missing link
Another recurring theme was the gap between coordination and true collaboration.
Many organizations are built to coordinate - through handoffs, approvals, and functional silos. Far fewer are structured to collaborate, with shared ownership and aligned incentives.
One concept that resonated was the need for a “conductor” - a role responsible for aligning teams around the customer, not just the process.
Without that alignment:
Insights remain fragmented
Decision-making slows
Innovation stalls
Commercial evolution: from B2B to B2B2C
Pharma’s commercial model is also evolving.
The traditional B2B approach is expanding toward B2B2C, recognizing the growing influence of patients in decision-making. However, this shift brings complexity:
New capabilities are required
Investment models must evolve
Financial commitment becomes a critical enabler
As one perspective put it candidly:
“If you don’t have the investment, the model breaks down.”
The reality of meaningful progress
Across conversations, one thing was clear:
The industry understands what needs to change. The challenge is execution.
Driving real impact requires:
Breaking down silos
Rethinking legacy processes, including rigid budgeting models
Letting go of control in favor of adaptability
Embracing experimentation - and learning from failure
It also requires accepting a fundamental truth:
Real progress is slower, more complex, and less comfortable than the appearance of progress.
But it is the only kind that delivers sustained value.
Final thought
The organizations that stood out were not necessarily the most advanced on paper. They were the ones:
Closest to patients
Most willing to listen
Most committed to acting on what they heard
Because ultimately:
Innovation isn’t defined by what you build -
but by what meaningfully changes outcomes for the people you serve.
Interested in hearing more? Connect with us here.